Jeffrey Abbey, President and CEO of Argos Therapeutics will provide the keynote address for ORIED’s annual Research Retreat at PNC Arena on April 5. Argos, an immuno-oncology company located in Durham, NC, develops and commercializes individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform. Argos recently signed a lease agreement for commercial manufacturing space on Centennial Campus. They plan to use the space to prepare a biologics license application to be submitted to the U.S. Food & Drug Administration and to support initial commercialization of rocapuldencel-T, the company’s most advanced product candidate.
With updates from
Save the date! Registration opens soon.
Jeffrey D. Abbey has served as President and Chief Executive Officer and a member of the board of directors of Argos Therapeutics since February 2010. Mr. Abbey served in various other positions at the company from September 2002 to February 2010, including Vice President of Business Development from February 2004 to January 2009 and Chief Business Officer from January 2009 to February 2010. Prior to joining Argos, Mr. Abbey served as Vice President of Business Development and Finance at Internet Appliance Network, an information technology company, from 1999 to 2001. Mr. Abbey was a partner at Eilenberg and Krause, LLP, a corporate law firm, from 1994 to 1999. Mr. Abbey received an A.B. in mathematical economics from Brown University and an M.B.A. and J.D. from the University of Virginia.